Abstract 113P
Background
Our real-world data show high response rates with the COIB regimen for mCRC (Liu, Ou et al. 2022). But the appropriate dosage needs to be carefully explored. Therefore, we designed this prospective phase I/II study to determine the efficacy and tolerability of this combination regimen in the first-line treatment of mCRC.
Methods
This study consists of dose escalation (DES) and dose expansion (DEX). The primary objective in DES phase was to evaluate safety and tolerability of I combined with COB, followed by a DEX phase to verify the safety and tolerability profile of the combination therapy. Primary endpoints included recommended phase ll dose (RP2D) and efficacy of the combination. Other end points included exploratory biomarkers of drug activity. I was administered once a day (QD) at two dose levels (150mg/㎡ or 165mg/㎡) in combination with C (1g/㎡ bid, day 1-7)+ O (85mg/㎡, day 1)+B (5mg/kg, day 1), every 14 days (Q2W).
Results
As of August 13, 2023, 97 pts (median age: 58 years; 30% female; 77% left-sided intestine; 43 KRAS mutation, 6 NRAS mutation, 4 BRAF mutation, 31 wild type, 13 unknown) were treated (6 in DES, 91 in DEX). None of the 3 pts in irinotecan dose level 1 or 3 pts in irinotecan dose level 2 of DES had dose limiting toxicities (DLTs), and irinotecan (165mg/㎡, day1) was the RP2D. Treatment-related adverse events (TRAEs) of any grade occurred in 87 (89.7%) pts. TRAEs of grade ≥ 3 were mainly myelosuppression (20 pts, 20.6%) and diarrhea (10 pts, 10.3%). There were no fatal TRAEs. Of 90 pts evaluable for response, Objective response rate (ORR) was 73.3% (95% CI: 64.1%, 82.4%), Disease control rate (DCR) was 98.8% (95% CI: 96.7%, 100.0%).22 patients were successfully transformed and underwent radical resection, No evidence of disease (NED) rate was 22.7% (95% CI: 14.4%, 31.0%). With median follow-up of 17.0 months, 46 pts had progressive disease, median progression free survival (PFS) was 13.0 months(95%CI: 10.8, 19.3), overall survival (OS) are not yet mature. Detection biomarkers of drug activity is in progress.
Conclusions
The RP2D of irinotecan in COIB regimen is 165 mg/m2. The efficacy of the regimen is promising with well tolerance.
Clinical trial identification
NCT04380103.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Development Project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences (CICAMS-MODP2022002).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract